Table 2.
Summary of findings table regarding the association of statin use with primary and secondary endpoints
| Endpoint | Studies no. | Sample size | Follow-up (months)† | RR (95% CI) | 95% prediction interval | I2 | Trim-fill method | GRADE assessment | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Missing studies | New RR (95% CI) |
Certainty of evidence | Downgrading | |||||||
| Efficacy | ||||||||||
| MACE | 6 | 3621 |
68.4 (48–72) |
0.87 (0.67–0.96) * | 0.67–0.96 * | 0% | 0 | 0.87 (0.67–0.96) * | Moderate | Study limitations |
| Mortality | 15 | 70,750 |
72 (3-180) |
0.84 (0.74–0.94) * | 0.65–1.08 | 40.4% | 1 | 0.84 (0.75–0.94) * | Low | Study limitations, inconsistency |
| Graft loss | 9 | 10,255 |
72 (3-180) |
0.72 (0.48–1.08) | 0.23–2.24 | 90.2% | 0 | 0.72 (0.48–1.08) | Very low | Study limitations, imprecision, inconsistency |
| Safety | ||||||||||
| Hepatotoxicity | 6 | 60,641 |
54 (3–72) |
0.81 (0.70–0.93) * | 0.70–0.93 * | 0% | 2 | 0.80 (0.70–0.92) * | Moderate | Study limitations |
| Creatine kinase elevation | 4 | 2624 |
40.5 (3–72) |
0.97 (0.50–1.89) | 0.50–1.89 | 0% | 1 | 1.02 (0.53–1.96) | Low | Study limitations, imprecision |
| Rhabdomyolysis | 2 | 59,801 |
54 (36–72) |
1.37 (1.10–1.70) * | 1.10–1.70 * | 0% | NA | NA | Low | Study limitations, imprecision |
| Diabetes mellitus | 4 | 58,597 |
48 (36-115.2) |
1.11 (0.38–3.27) | 0.11–11.07 | 92.4% | 1 | 0.79 (0.26–2.39) | Very low | Study limitations, imprecision, inconsistency |
| Cataract | 1 | 57,699 | 36 | 1.22 (1.14–1.31) * | NA | NA | NA | NA | Moderate | Study limitations |
| Hip fracture | 2 | 15,846 |
8 (4–12) |
0.90 (0.68–1.20) | 0.68–1.20 | 0% | NA | NA | Low | Study limitations, imprecision |
| Venous thromboembolism | 1 | 1384 | 12 | 0.92 (0.39–2.19) | NA | NA | NA | NA | Low | Study limitations, imprecision |
| Cancer | 1 | 2102 | 72 | 0.94 (0.82–1.07) | NA | NA | NA | NA | Moderate | Imprecision |
Asterisks denote statistically significant results
†Median (range); MACE: major adverse cardiovascular events; RR: relative risk; CI: confidence intervals: I2: inconsistency index; GRADE: Grading of Recommendations, Assessment, Development, and Evaluations; NA: not applicable